Half-year report · Q2
6095.TEDINET S100VQUM
Period2024-10-01 → 2025-03-31
Filed2025-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥629m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥14.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥149m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥93m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥360m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.65 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | revenue external | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | segment profit | 2024-10-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥683m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥964m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥72m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥393m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥38m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥6.2bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥74m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥1.3bn |
| Otherother segments | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| Otherother segments | segment profit | 2023-10-01 → 2024-03-31 | ¥159m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥679m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥967m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥10m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥520m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥6.7bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥23m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration | 6312369000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 963869000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 393423000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | -38422000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 1318870000 | JPY |
| Operating income | CurrentYTDDuration_OtherReportableSegmentsMember | -6084000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -683347000 | JPY |
| Operating income | CurrentYTDDuration | 629439000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-05-15 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期中（自 2024年10月１日 至 2025年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)メドピア株式会社 | |
| Company name in english cover page | FilingDateInstant | MedPeer, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 兼 執行役員社長CEO 後藤 直樹 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区築地一丁目13番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-4405-4905 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 兼 執行役員 CFO 平林 利夫 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区築地一丁目13番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-4405-4905 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 兼 執行役員 CFO 平林 利夫 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E30650 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 60950 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)メドピア株式会社 | |
| Filer name in english | FilingDateInstant | MedPeer, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-10-01 | |
| Current period end date | FilingDateInstant | 2025-03-31 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-09-30 | |
| Previous fiscal year start date | FilingDateInstant | 2023-10-01 | |
| Comparative period end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-09-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |